Le Lézard
Classified in: Health
Subjects: MAV, EXE, NTA, FVT

Media Advisory - MP Paul Lefebvre to make an announcement for healthy aging in Indigenous populations


SUDBURY, ON, Dec. 3, 2017 /CNW/ - Mr. Paul Lefebvre, Member of Parliamentary for Sudbury, on behalf of the Honourable Ginette Petitpas Taylor, Minister of Health, will announce funding for an innovative research project on aging in Indigenous populations.   

 

Date:

December 4, 2017                 



Time:

9:00 a.m.        



Location:

Health Sciences North, Ramsey Lake Health Centre


Lecture Rooms A, B, and C


41 Ramsey Lake Road


Sudbury, ON 

                       

SOURCE Canadian Institutes of Health Research


These press releases may also interest you

at 05:25
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...



News published on and distributed by: